Sophie Delhomme

Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau et al. · The Lancet · 2017 · 269 citations

Veterinary Medicine, Biology, Infectious Diseases +15

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial

Victor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Sandra Rembry et al. · The Lancet Infectious Diseases · 2022 · 116 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacology +17

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau et al. · The Lancet Global Health · 2021 · 56 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +16

Biodegradable microparticles for sustained release of a new GnRH antagonist – part I: screening commercial PLGA and formulation technologies

G. Schwach, Nathalie Oudry, Sophie Delhomme et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2003 · 50 citations

Pharmacy, Pharmaceutics, Pharmacology +17

Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects

Jean‐Yves Gillon, Jeremy Dennison, Frans van den Berg et al. · British Journal of Clinical Pharmacology · 2021 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10